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Purpose—To dynamically detect and characterize 18F-fluorodeoxyglucose (FDG) dose 
infiltrations and evaluate their effects on positron emission tomography (PET) standardized uptake 
values (SUV) at the injection site and in control tissue.
Methods—Investigational gamma scintillation sensors were topically applied to patients with 
locally advanced breast cancer scheduled to undergo limited whole-body FDG-PET as part of an 
ongoing clinical study. Relative to the affected breast, sensors were placed on the contralateral 
injection arm and ipsilateral control arm during the resting uptake phase prior to each patient’s 
PET scan. Time activity curves (TACs) from the sensors were integrated at varying intervals (0–
10, 0–20, 0–30, 0–40, and 30–40 min) post-FDG and the resulting areas-under-the-curve (AUCs) 
were compared to SUVs obtained from PET.
Results—In cases of infiltration, observed in three sensor recordings (30%), the injection arm 
TAC shape varied depending on the extent and severity of infiltration. In two of these cases TAC 
characteristics suggested the infiltration was partially resolving prior to image acquisition, 
although it was still apparent on subsequent PET. Areas under the TAC 0–10 and 0–20 min post-
FDG were significantly different in infiltrated versus non-infiltrated cases (Mann-Whitney, p < 
0.05). When normalized to control, all TAC integration intervals from the injection arm were 
significantly correlated with SUVpeak and SUVmax measured over the infiltration site (Spearman ρ 
≥ 0.77, p < 0.05). Receiver operating characteristic (ROC) analyses, testing the ability of the first 
10 minutes of post-FDG sensor data to predict infiltration visibility on the ensuing PET, yielded an 
area under the ROC curve of 0.92.
Conclusion—Topical sensors applied near the injection site provide dynamic information from 
the time of FDG administration through the uptake period and may be useful in detecting 
infiltrations regardless of PET image field of view. This dynamic information may also 
complement the static PET image to better characterize the true extent of infiltrations.
Keywords
Infiltration; Extravasation; Standardized Uptake Value Accuracy; Time Activity Curve; Topical 
Scintillation Device; Radiotracer Injection
Introduction
18F-Fluorodeoxyglucose (FDG) PET/CT plays a pivotal role in cancer care. A widely used 
parameter to quantify FDG uptake is the standardized uptake value (SUV), calculated by 
normalizing FDG activity concentration in a volume of interest (VOI) to the decay-corrected 
injected activity and body mass. SUVs allow semi-quantitative evaluation of disease and 
therapy response. Accuracy of SUV estimation assumes the entire net injected dose is 
administered intravenously as a bolus injection. Improper injections can result in 21–50% 
change in SUV measurements [1, 2]. A recent summary of findings from six prospective, 
randomized controlled studies evaluating peripheral IV catheter infiltration rates found a 
mean incidence of 23.9% [3]. In the few published studies measuring infiltration rates in 
PET, tracer infiltration occurs in 10–21% of clinical exams [2, 4, 5].
Dose infiltrations are particularly concerning in oncology where venous integrity is often 
compromised due to disease and/or therapy. Moreover, the antecubital vein—the most 
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common FDG injection site—is often excluded from the commonly-used PET base-of-skull 
to mid-thigh field of view (FOV), as standard body imaging is performed with arms raised to 
avoid artefacts in CT-based attenuation correction [6]. Infiltrations may thus go undetected 
and unreported, as demonstrated in a recent study where 31% of those detected occurred 
outside the base-of-skull to mid-thigh FOV [4], and documentation of the injection site 
location relative to the FOV was missing in at least 8% of oncologic PET reports [7].
Failing to account for, report, or even detect dose infiltrations confounds SUV measurements 
by overestimating injected tracer activity [1] and by underestimating the time that FDG is 
available for tissue uptake, which severely hinders the quantitative use of PET. We tested the 
hypothesis that an investigational gamma radiation detection system [8] applied to the skin 
near the FDG injection site could dynamically detect and characterize the occurrence of 
infiltrations during the uptake phase preceding whole-body PET/CT.
Materials and methods
Patients
Eight women with locally advanced breast carcinoma participating in a clinical trial 
(ClinicalTrials.gov NCT01222416) examining FDG-PET/CT for early prediction of 
neoadjuvant therapy response [9] consented to this study, which was approved by the 
Institutional Review Board. Two patients had a follow-up FDG-PET/CT as part of the parent 
trial, resulting in a total of 10 datasets.
Sensor application and FDG-PET/CT
PET/CT was performed according to standard protocols [6]. After confirming fasting blood 
glucose (median 92.5 mg/dl, range 83 – 117, n = 10) and gaining venous access (antecubital 
vein, n = 9; metacarpal vein, n = 1), investigational scintillation sensors [8] (Lucerno 
Dynamics, LLC, Morrisville, NC, USA; Fig. 1) were attached topically with medical tape in 
three locations: over the tumour, 10 cm above the antecubital fossa contralateral to the 
tumour (injection arm), and 10 cm above the ipsilateral antecubital fossa (control arm). The 
unshielded sensors contain a Bismuth Germanate crystal with corresponding photodetector, 
resulting in an iso-sensitivity profile that is approximately spherical, with a centre located at 
the centre of the detector face. Activity recording from the sensors was initiated 
approximately 60 s prior to injection of FDG (median 453 MBq, range 359 – 522, n = 10) 
followed by a 10–20 ml saline flush. Administration of FDG was performed by five 
Certified Nuclear Medicine Technologists having a median of 13 (range 5 – 20) years of 
experience. Patients remained inactive in a dimmed room while sensor data were recorded 
during the resting uptake period. Sensors operated in 2-second cycles: 1 second to count the 
activity followed by 1 second to record the data. Near the end of the uptake period (42 – 59 
min post-FDG) sensors were removed, and patients underwent limited whole-body PET/CT 
(i.e., top-of-skull to mid-thigh FOV) in a Discovery STE scanner (GE Healthcare, 
Waukesha, WI, USA) as previously described [10].
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Data analysis
Areas under the time activity curve (TAC), in units of integrated counts, were computed over 
various intervals, including the initial bolus FDG infusion (median 0.8 min post-injection; 
range 0.3 – 1.9 min), as well as fixed time intervals of 0–10, 0–20, 0–30, 0–40, and 30–40 
min post-injection. For these intervals, the ratio of the injection arm TAC area to the control 
arm TAC area was computed, and referred to as the I/C ratio (i.e., injection to control ratio). 
The median (± 95% confidence interval) I/C ratio for the last 10 min of sensor recordings, 
the portion of the TAC closest in time to PET, was computed; the upper confidence limit 
served as a threshold for detection. PET data were converted to SUVs on a voxel-wise basis 
according to standard methods [11]. VOIs were drawn over the antecubital fossa and right 
hepatic lobe (background) to compute the maximum single-voxel SUV in the VOI (SUVmax) 
and the mean value of a 1 cm3 sphere placed in the most FDG-avid portion of the VOI 
(SUVpeak), which also included SUVmax [12]. Data underwent nonparametric group 
comparisons in Prism (GraphPad, La Jolla, CA, USA); correlation analyses, and receiver 
operating characteristic (ROC) analyses in Matlab (Mathworks, Natick, MA, USA). For 
ROC analyses, the visibility of an infiltration on the PET image served as the ‘gold 
standard’. Maximum intensity projections (MIPs) were generated in OsiriX (OsiriX 
Foundation, Geneva, Switzerland).
Results
In ten sensor-PET data pairs, FDG infiltration was detected in three TACs (30%). A fourth 
scan featured a FDG spot at the site of injection. This spot was low in intensity and volume 
and was not detected by the sensor but was observable on PET only. Sensor data were 
collected for a median of 51.6 min (range 42.1 – 60.0). The median duration from FDG 
injection to start of PET was 73.1 min (range 60.0 – 80.9).
Fig. 2 depicts TACs obtained from sensor recordings in five illustrative cases. Supplemental 
Figure 1 includes sensor data TACs from the injection and control arms for all 10 cases. The 
injection arm TAC (red trace, top) was normalized point-by-point to the control arm TAC 
(blue trace, top) to determine the injection/control (I/C) ratio (purple trace, bottom). In the 
six scans where no infiltration was visible on PET, the median (± 95% confidence interval) 
I/C ratio for the last 10 min of sensor recordings was 1.14 (± 0.21). The upper confidence 
limit (I/C ratio = 1.35) denotes a convenient reference threshold for infiltration detection 
(black dotted line).
The patient shown in Case 1 had no detectable evidence of infiltration based on the injection 
arm and control arm sensor TACs (Fig. 2a). This patient experienced a steep rise and fall and 
large amplitude of the injection arm TAC during the first 45 s post-FDG administration and 
was consistent with the kinetics of an unimpeded intravenous bolus (Fig. 2a). In sharp 
contrast, the patient shown in Case 2 experienced severe, persistent dose infiltration at the 
injection site, as suggested by the shallow slope of the injection arm TAC and approximately 
19-fold greater area under the TAC relative to the control arm (Fig. 2b). Case 3 had 
moderate dose infiltration that resolved to a small infiltration during the uptake period and 
approximately 2-fold greater area under the TAC relative to control (Fig. 2c). The patient in 
Case 4 initially exhibited a severe infiltration that resolved to a moderate infiltration prior to 
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the PET scan and approximately 9-fold greater area under the TAC relative to control (Fig. 
2d). In Case 5, a small spot of FDG near the site of injection was evident on PET (see 
below), but, because the injection arm sensor was placed 10 cm proximal, the spot was not 
detected and the TAC shape appeared normal (Fig. 2e).
Fig. 3 shows maximum intensity projections (MIPs), obtained from PET acquisitions that 
followed the sensor data acquisitions, for each of the five illustrative cases in Fig. 2. Case 1 
had no visible evidence of infiltration on PET (Fig. 3a); the median (± 95%CI) injection site-
to-background (liver) SUVpeak ratio for the six non-infiltrated scans was 0.38 (± 0.069). 
Conversely, Case 2 exhibited severe infiltration in the antecubital fossa, with 674-fold higher 
SUVpeak in the injection arm versus liver (Fig. 3b). Case 3, where the sensor data suggested 
the infiltration had resolved to a low level, had residual FDG uptake in the antecubital fossa 
that was 3.3-fold higher relative to liver (Fig. 3c). For Case 4, where the sensor data 
indicated a severe infiltration that resolved to a moderate infiltration by the end of the uptake 
period, moderate FDG infiltration was visible in the antecubital fossa, which had a SUVpeak 
at least nine times higher than liver (Fig. 3d). As mentioned above, a small FDG spot was 
visible in the injection site for Case 5, with an SUVpeak approximately 1.5 times higher than 
liver (Fig. 3e).
Supplemental Table 1 summarizes the various sensor TAC integration metrics obtained from 
the injection and control arm sensors, as well as SUVmax and SUVpeak measurements 
obtained from antecubital fossa of the injection arm and right liver lobe background for all 
10 PET scans. Fig. 4 summarizes results of nonparametric statistical comparisons (Mann-
Whitney test) of sensor and PET data obtained in PET-visible infiltration (n = 4) versus non-
infiltration (n = 6) groups. Following the initial FDG infusion peak, significant differences 
(p < 0.05) between infiltrated and non-infiltrated groups were apparent for the 0–10 min and 
0–20 min sensor TAC integration metrics as well as the PET SUV metrics (Fig. 4). Table 1 
summarizes the nonparametric (Spearman) correlation analyses of sensor TAC integration 
and PET SUV measurements, which collectively show that, by normalizing the injection 
arm data to control data, the correlation is improved; all sensor TAC integration I/C ratios 
were significantly correlated with antecubital fossa SUVpeak and SUVmax normalized to 
liver (Spearman ρ ≥ 0.77, p < 0.05). Receiver operating characteristic (ROC) analyses, 
summarized in Table 2, were conducted to determine the diagnostic capabilities of the 
sensors to predict whether an infiltration would be visible on the subsequent PET image. 
Data collected over the first 10 and 20 minutes post-FDG were most predictive, resulting in 
an area under the ROC curve of 0.92.
Discussion
This is the first report demonstrating the feasibility of topically applied scintillation sensors 
for detecting and characterizing FDG dose infiltrations in real time. We showed five 
examples where the shape of the sensor TAC yielded dynamic information regarding the 
amount of FDG counts recorded approximately 10 cm from the injection site (Fig. 2). 
Statistically significant differences (p < 0.05) between infiltrated and non-infiltrated TACs 
were observed in the first 20 min following FDG injection (Fig. 4). Additionally, TAC 
integration metrics 0–40 min post-FDG were significantly correlated (p < 0.05) with PET 
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SUVs when the parameters were normalized to their respective background, e.g., injection 
arm/control arm for TAC integrations and antecubital fossa/liver VOIs for PET SUVs (Table 
1). Furthermore, ROC analyses indicated that information obtained from the sensors, even 
within the first 10 min following the initial administration of FDG, had a high degree of 
accuracy for predicting the appearance of infiltration in the subsequent PET scan (Table 2). 
Given the frequency of infiltrations, which have ranged from 10–24% [2–5], these findings 
highlight the value of sensitive methods capable of quantitatively reporting on the fidelity of 
intravenous radiotracer injection before image acquisition as an important quality control 
procedure to verify the clinical reliability of the SUVs obtained from the PET scan.
Quantitative PET requires rigorous standardization of image acquisition and analysis [1, 12, 
13]. Underscoring this point, a recent multicentre study of non-small cell lung cancer found 
a 30% SUV decrease (in defining therapeutic response) or a 40% SUV increase (in defining 
progression) is required to have confidence that the results are indicative of metabolic 
response or metabolic progression, rather than a reflection of the variability in the PET/CT 
measurement process [14]. It is likely that infiltration of FDG at the injection site would 
contribute to this variability [1, 2]. An infiltration reduces the delivered dose and reduces the 
available uptake time in ways that cannot be accurately accounted for using information in a 
static PET image. The results from the current study suggest that lower metabolic response 
thresholds for PET may be achievable if the variability introduced by infiltrations is reduced. 
Indeed, considering the range of temporal manifestations (e.g., persisting or resolving 
throughout the uptake period, Fig. 2b–d), the occurrence of an infiltration would likely 
completely invalidate the use of SUVs in the study, since they cannot be accurately corrected 
post hoc.
While clinical impressions for staging disease based upon PET are generally qualitative, 
quantitative data are essential in therapy response evaluation and would undoubtedly also 
improve disease staging [12]. Topical scintillation sensors may provide immediate feedback 
regarding the onset and severity of an infiltration in ways that could be critically useful in 
PET. Identifying severe infiltrations at the end of the uptake period is not a challenge if the 
injection site is in the FOV; the PET image shows the infiltration, confirmed by the sensor 
data. Perhaps the more useful aspect is identification of cases where the infiltration was 
severe for an appreciable part of the uptake period, but resolves towards the end. In these 
cases, even if the injection site is in the PET FOV, PET data would understate the extent of 
the infiltration, but dynamic sensor data from the uptake period would identify it clearly. For 
this reason, sensor data could provide a valuable and currently unavailable characterization 
of an infiltration.
Providing feedback on the fidelity of an FDG injection could help reduce erroneous 
interpretations and provide options, not available currently, for clinicians in the management 
of their patients. In non-quantitative studies, awareness of a resolving infiltration before PET 
acquisition may provide clinicians the opportunity to prolong the uptake period. Having 
visibility to severe infiltrations that resolve dramatically prior to PET imaging provides 
clinicians information that may lead to repeating critically important scans.
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The preliminary findings presented here have certain inherent limitations. One is that the 
study includes only a small number of matched observations (n = 10) and, perhaps owing to 
this, a potentially higher infiltration rate (30% confirmed by both sensors and PET) than 
might be expected. This is in contrast to the infiltration rate seen in studies with larger 
patient cohorts (11–21% confirmed by PET alone) [2, 4, 5]. A further limitation of this study 
is related to the placement of the sensor with respect to the injection site. In a follow-on, 
multicentre clinical assessment of approximately 400 patients since the evaluation of the 
device at Vanderbilt began, infiltration rates of ~22% have been confirmed (unpublished 
data). In this same study, placement of the sensors approximately 7 cm from the injection 
site has provided improved sensitivity allowing for the detection of residual FDG in 
indwelling catheters. A similar approach of surface detection at locations proximal to the 
venous access site has also been demonstrated with technetium-99m probes [15].
In the future, additional studies will provide insight regarding other important possibilities 
that arise from this work. Due to the unshielded nature of the detectors, the use of sensor 
ratios (i.e., injection arm/control arm) to establish detection thresholds for predicting 
infiltration visibility on PET could be influenced by physiologic and/or pathologic uptake of 
FDG into nearby organs, an effect which needs further investigation. Additionally, studies 
assessing the impact of infiltrations on quantification using reference regions, dynamic TAC 
sensor data, and quantitative dynamic modelling could provide additional insight as to the 
consequences of infiltration. Finally, a third possible use of the sensors that would be of 
particular interest for dynamic PET studies would be to provide an estimate of the arterial 
input function without the need for invasive blood sampling.
In conclusion, it is evident that failing to account for FDG dose infiltration would lead to 
quantitative errors in SUV estimates and would also influence qualitative interpretations of 
PET scans. Since a static PET image is incapable of characterizing the quality of FDG 
administration during the preceding ~60 min uptake period, topical scintillation sensors 
could provide a simple as well as economical approach for real-time feedback on the 
occurrence and extent of dose infiltration.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
(a) Sensors containing scintillation material convert gamma radiation, emitted from the 
decay of 18F-FDG, to visible light in the form of photon counts/sec. For recordings of the 
injection arm and control arm, sensors are positioned over the bicep, since the convex shape 
of the antecubital fossa hinders direct recording from this region. Sensors are held in place 
using standard medical tape. (b) Sensors are connected via cable to a portable reader module 
that actively records activity counts at 1-second intervals. Data from each sensor channel (up 
to four) are digitized, tabulated and exported from the reader in a variety of formats for 
further computational analysis.
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Fig. 2. 
Time activity curves (TACs) from sensors placed over the injection arm (red) were 
normalized to those obtained on the control arm (blue) to determine the I/C ratio (purple) in 
a patient with no visible infiltration (a) and patients with severe (b), moderate that resolves 
to small (c), and severe that resolves to moderate (d) infiltration. PET data corresponding to 
each of these cases are found in Fig. 3. One patient (e) had a low activity spot of FDG, 
visible on PET (Fig. 3e), but TAC data were inconclusive due to sensor distance from this 
spot. Note the differential ordinate scaling; see Supplemental Figure 1 for TAC data from all 
10 scans.
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Fig. 3. 
Maximum intensity projections from PET images, corresponding to the sensor time activity 
curves (TACs) in Fig. 2, illustrate the antecubital injection site (red), hepatic control site 
(blue), and tumour (green arrow) in a patient with no visible infiltration (a) and patients with 
severe (b), small (c), and moderate (d) infiltration. One patient (e) had a low activity spot of 
FDG that was not detected by the sensor, but TAC data (Fig. 2e) were inconclusive due to 
sensor distance to this spot.
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Fig. 4. 
Injection arm (I) sensor TAC areas were normalized to control arm (C) sensor TAC areas to 
compute the I/C Ratio over a range of intervals during the uptake period (Peak only; 0–10; 
0–20; 0–30; 0–40; and 30–40 post-FDG). Significant differences between infiltrated (dark 
bars) and non-infiltrated (open bars) were observed in the 0–10 and 0–20 min post-FDG 
intervals (p<0.05 Mann-Whitney test).
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